HitIQ Limited (AU:HIQ)
ASX:HIQ
Want to see AU:HIQ full AI Analyst Report?
Top Page
HitIQ Limited
(Sydney:HIQ)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.01
▼(-45.00% Downside)
Action:ReiteratedDate:03/25/26
Overall score is pressured primarily by poor financial performance (large losses, negative equity, and negative cash flows). Technicals also weaken the outlook with a downtrend versus key moving averages and negative MACD, while valuation offers limited support due to a negative P/E and no dividend yield data.
Positive Factors
Recurring hardware + software model
HitIQ combines instrumented mouthguards with subscription analytics, creating a mixed hardware plus recurring software revenue model. This structure supports longer-term, predictable revenue, higher lifetime value per customer, and recurring service relationships that aid retention and upsell over multiple seasons.
Negative Factors
Weak balance sheet / negative equity
The balance sheet shows negative shareholders' equity and a -1.41 debt-to-equity metric, indicating capital structure stress. This constrains financial flexibility, increases refinancing or dilution risk, and limits capacity to fund product development, sales scaling, or absorb demand shocks without external capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring hardware + software model
HitIQ combines instrumented mouthguards with subscription analytics, creating a mixed hardware plus recurring software revenue model. This structure supports longer-term, predictable revenue, higher lifetime value per customer, and recurring service relationships that aid retention and upsell over multiple seasons.
Read all positive factors
HitIQ Limited (HIQ) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$9.07M
Dividend YieldN/A
Average Volume (3M)233.78K
Price to Earnings (P/E)―
Beta (1Y)0.27
Revenue Growth-57.91%
EPS Growth-9.02%
CountryAU
Employees25
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding756,219,300
10 Day Avg. Volume147,164
30 Day Avg. Volume233,782
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-1.60
Price to Sales (P/S)3.20
P/FCF Ratio-1.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HitIQ Limited Business Overview & Revenue Model
Company Description
HitIQ Limited engages in development and commercialization of concussion management technology in Australia. Its Nexus software provides comprehensive head impact data and analysis to make informed decisions to improve the quality of care for athl...
How the Company Makes Money
HitIQ makes money primarily by selling its head-impact monitoring solution to sports organizations. Revenue is generated from (1) hardware sales of its sensor-enabled mouthguards, and (2) recurring software/analytics revenue associated with provid...
HitIQ Limited Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
20
Very Negative
Cash Flow
30
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.23M | 2.01M | 4.75M | 774.26K | 619.02K | 406.68K |
| Gross Profit | -956.20K | -2.18M | 334.63K | 242.73K | 243.43K | -3.28M |
| EBITDA | -6.60M | -5.99M | -2.54M | -4.31M | -6.54M | -4.79M |
| Net Income | -7.02M | -7.21M | -3.20M | -5.04M | -6.95M | -5.06M |
Balance Sheet | ||||||
| Total Assets | 1.46M | 3.28M | 3.73M | 3.13M | 4.55M | 9.49M |
| Cash, Cash Equivalents and Short-Term Investments | 359.17K | 990.96K | 584.02K | 1.98M | 2.94M | 8.96M |
| Total Debt | 1.53M | 5.66M | 3.20M | 1.69M | 2.16M | 709.34K |
| Total Liabilities | 6.64M | 7.30M | 5.20M | 3.18M | 3.38M | 1.56M |
| Stockholders Equity | -5.18M | -4.02M | -1.47M | -46.86K | 1.17M | 7.92M |
Cash Flow | ||||||
| Free Cash Flow | -5.02M | -4.68M | -4.12M | -4.57M | -6.57M | -2.18M |
| Operating Cash Flow | -5.01M | -4.65M | -4.10M | -4.51M | -6.51M | -2.13M |
| Investing Cash Flow | -7.20K | -28.57K | -20.78K | -54.73K | -918.06K | -54.84K |
| Financing Cash Flow | 4.71M | 5.09M | 2.73M | 3.61M | 1.41M | 10.71M |
HitIQ Limited Technical Analysis
Negative
0.02
Price Trends
0.02
Negative
0.02
Negative
0.02
Negative
Market Momentum
>-0.01
Positive
40.79
Neutral
-50.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HIQ, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.02, and above the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.79 is Neutral, neither overbought nor oversold. The STOCH value of -50.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:HIQ.
HitIQ Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$22.42M | 3.95 | 7.57% | ― | 31.36% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$40.33M | -4.21 | -52.26% | ― | 22.81% | -110.26% | |
46 Neutral | AU$15.55M | -2.48 | -578.72% | ― | 43.55% | 26.03% | |
43 Neutral | AU$66.35M | -6.64 | -59.96% | ― | ― | ― | |
41 Neutral | AU$9.07M | -0.96 | 152.58% | ― | -57.91% | -9.02% | |
41 Neutral | AU$4.23M | -1.98 | 20.02% | ― | -5.76% | 8.00% |
* Healthcare Sector Average
AU:HIQ
HitIQ Limited
0.01
-0.01
-52.00%
AU:RHT
Resonance Health Ltd
0.05
<0.01
14.63%
AU:GLH
Global Health Limited
0.07
-0.02
-20.00%
AU:SHG
Singular Health Group Ltd
0.21
-0.08
-28.81%
AU:EMD
Emyria Ltd
0.05
0.02
78.57%
AU:ICR
InteliCare Holdings Limited
0.03
0.02
150.00%
HitIQ Limited Corporate Events
HITIQ Seeks Extended Suspension of HIQOA Options Pending Court Application
Apr 30, 2026
HITIQ Limited has requested an immediate extension to the voluntary suspension of its HIQOA listed options on the ASX, as it finalises an application to the Federal Court under section 1322 of the Corporations Act. The application seeks more time ...
HITIQ Signs NRL Halfback Jamal Fogarty as Ambassador to Promote Concussion Tech
Apr 27, 2026
HITIQ Limited has appointed Manly-Warringah Sea Eagles halfback Jamal Fogarty as a brand ambassador for the 2026 NRL season, strengthening its push to expand adoption of its PROTEQT concussion management platform across rugby league. Fogarty, a re...
HitIQ accelerates PROTEQT rollout with national retail launch and surging quarterly sales
Apr 26, 2026
HitIQ reported a sharp acceleration in commercial traction for the March quarter, with sales rising to $294,000 from $91,000 as the PROTEQT™ mouthguard platform secured national retail distribution through Rebel, Chemist Warehouse Marketplac...
HitIQ Seeks Court Orders and Extended Suspension for HIQOA Options
Apr 22, 2026
HitIQ Limited has asked the ASX to extend the voluntary suspension of its HIQOA listed options as it moves to resolve a technical issue linked to their admission to quotation. The options were issued under a 15 May 2025 prospectus and are currentl...
HitIQ plans placement of up to 500,000 new shares
Apr 20, 2026
HitIQ Limited has notified the ASX of its intention to issue up to 500,000 new ordinary fully paid shares under a proposed placement or similar type of securities issue. The new shares are expected to be issued on 1 May 2026, indicating a forthcom...
HitIQ taps AFLW star Ebony Marinoff to champion PROTEQT head-impact tech
Apr 20, 2026
HitIQ Limited has appointed Adelaide Crows AFLW star and co-captain Ebony Marinoff as a PROTEQT brand ambassador, leveraging her status as one of the competition’s most decorated and durable players. Marinoff already wears the PROTEQT mouthg...
HitIQ Plans Issue of 1 Million Convertible Notes on ASX
Apr 16, 2026
HitIQ Limited has lodged a new Appendix 3B with the ASX outlining a proposed placement of up to 1,000,000 convertible notes under the security code HIQAT. The issue is scheduled for 16 June 2026, signaling the company’s intention to access a...
HITIQ Secures $1m Shareholder-Backed Loan Ahead of Planned Convertible Note Issue
Apr 16, 2026
HITIQ Limited has secured a $1 million loan from major shareholder–associated entity No Bull Health, linked to Harmil Angel Investments, to provide near-term working capital and support ongoing operations. An initial $250,000 has already bee...
HitIQ Seeks Extension of Voluntary Suspension on HIQOA Options Pending Court Ruling
Apr 15, 2026
HitIQ Limited has requested an immediate extension to the voluntary suspension of its HIQOA listed options on the ASX, as it finalises an application to the Federal Court under the Corporations Act to extend the deadline for their admission to quo...
HITIQ Seeks Extended Suspension of HIQOA Options Pending Court Application
Apr 9, 2026
HITIQ Limited has requested an immediate extension to the voluntary suspension of its HIQOA listed options on the ASX, as it finalises a Federal Court application under section 1322 of the Corporations Act. The application seeks an extension of th...
HitIQ Director Boosts Indirect Stake Through Major Note Conversion
Apr 8, 2026
HitIQ Limited has disclosed a significant change in director Matthew Clayworth’s interests, following the conversion of convertible notes into fully paid ordinary shares held through Harmil Angel Investments Pty Ltd. The transaction, approve...
HITIQ Clears 123 Million New Shares for Trading With Compliance Notice
Apr 7, 2026
HITIQ Limited has issued 123,388,031 fully paid ordinary shares on 7 April 2026 under provisions of the Corporations Act that allow the placement to proceed without a disclosure document to investors. The board confirmed the company remains compli...
HitIQ Seeks ASX Quotation for 123 Million New Shares After Note Conversion
Apr 7, 2026
HitIQ Limited has applied to the ASX for quotation of 123,388,031 new ordinary fully paid shares, issued on April 7, 2026. The shares result from a partial conversion of an existing convertible note, as approved at the company’s February 6, ...
HitIQ Seeks Extension of Trading Suspension on HIQOA Listed Options Amid Court Application
Mar 31, 2026
HitIQ Limited has requested an immediate extension to the voluntary suspension of trading in its HIQOA listed options on the ASX, as it finalises a Federal Court application concerning the timing of their admission to quotation. The options were i...
HitIQ Director Earl Eddings Increases Direct Shareholding via On‑Market Purchase
Mar 27, 2026
HitIQ Limited has disclosed a change in the securities held by director Earl Eddings, who has increased his direct shareholding in the company. Eddings purchased 100,000 fully paid ordinary shares on-market at $0.016 per share, lifting his direct ...
HitIQ Seeks Extension of Voluntary Suspension for HIQOA Listed Options
Mar 23, 2026
HitIQ Limited has requested an immediate extension to the voluntary suspension of its HIQOA listed options on the ASX while it finalises a Federal Court application under section 1322 of the Corporations Act. The application seeks more time for th...
HITIQ Updates Registered Office as It Advances Concussion Safety Tech
Mar 17, 2026
HITIQ Limited has updated its registered office address to new premises in South Melbourne, Victoria, effective immediately, as required under ASX listing rules. The administrative change is not expected to alter the company’s operations but...
HitIQ Seeks Extension of Voluntary Suspension on HIQOA Listed Options
Mar 16, 2026
HitIQ Limited has requested an immediate extension to the voluntary suspension of its HIQOA listed options on the Australian Securities Exchange. The company has made this move in connection with an issue under specific sections of the Corporation...
HITIQ Director Boosts Equity Stake Through Fee-for-Shares Arrangement
Mar 10, 2026
HITIQ Limited has reported a change in director Matthew Clayworth’s interests, following the issue of securities in lieu of director’s fees. Clayworth received 477,273 fully paid ordinary shares and an equal number of performance right...
HitIQ seeks extension of trading suspension on HIQOA listed options
Mar 9, 2026
HitIQ Limited has requested an immediate extension to the voluntary suspension of its HIQOA listed options on the ASX, citing issues related to the Corporations Act provisions governing the December 2025 issue of those options. The suspension is i...
HitIQ Issues New Shares Under Disclosure Exemption, Confirms Regulatory Compliance
Mar 6, 2026
HitIQ Limited has issued 2,511,994 fully paid ordinary shares on 6 March 2026 and has confirmed that this issuance was conducted without a prospectus or product disclosure statement under the exemption provisions of the Corporations Act. The compa...
HitIQ Issues 1.43 Million New Performance Rights
Mar 6, 2026
HitIQ Limited has notified the ASX of the issue of 1,431,819 unquoted performance rights, recorded under the code HIQAU, with an issue date of March 6, 2026. The move reflects the company’s ongoing use of equity-based instruments, likely for...
HitIQ Seeks ASX Quotation for Shares Issued in Lieu of Directors’ Fees
Mar 6, 2026
HitIQ Limited has applied to the ASX for quotation of 1,830,176 new ordinary fully paid shares, to be traded under its existing ticker HIQ. The shares were issued on 6 March 2026 as non-cash remuneration in lieu of directors’ fees, following...
HitIQ Seeks ASX Quotation for New Shares and Long-Dated Options
Mar 6, 2026
HitIQ Limited has applied to the ASX for quotation of 681,818 new ordinary fully paid shares and 340,909 options expiring on 30 December 2028, with an issue date of 6 March 2026. The move reflects an expansion of the company’s listed capital...
HitIQ director Earl Eddings lifts stake with on-market share purchases
Mar 5, 2026
HitIQ Limited has disclosed a change in the shareholding of director Earl Eddings, who increased his direct and indirect holdings through on-market purchases. Eddings acquired a total of 500,000 fully paid ordinary shares at $0.015 per share, lift...
HitIQ’s PROTEQT Widens Retail Reach with National Campaign and First Overseas Rugby Order
Mar 5, 2026
HitIQ’s PROTEQT head impact protection product has expanded into a broad multi-channel retail network, now sold via rebel stores nationwide, Chemist Warehouse Marketplace, Amazon Marketplace Australia, and through an agreement with NARTA tha...
HitIQ Director Boosts Indirect Stake via Major Note Conversion
Mar 3, 2026
HitIQ Limited has disclosed a substantial change in director Matthew Clayworth’s interests following the conversion of convertible notes into equity. Through Harmil Angel Investments Pty Ltd, where he is the nominated board representative, C...
HitIQ Seeks Extension of Voluntary Suspension on HIQOA Listed Options
Mar 2, 2026
HitIQ Limited has requested an immediate extension to the voluntary suspension of trading in its HIQOA listed options on the ASX, citing issues related to the issuance of those options on 22 December 2025 under specific sections of the Corporation...
HITIQ Clears 1.78 Million New Shares for Trading Under Disclosure Exemption
Mar 1, 2026
HITIQ Limited has issued 1,780,000 fully paid ordinary shares on 27 February 2026 without a prospectus, relying on provisions of the Corporations Act that allow such an issue to be made without formal disclosure to investors. The company states it...
HitIQ Issues 5.66 Million Unquoted Performance Rights Under Incentive Scheme
Mar 1, 2026
HitIQ Limited has notified the market of the issue of 5,660,000 unquoted performance rights under its employee incentive scheme, with an issue date of 27 February 2026. The new performance rights, which are not intended to be quoted on the ASX, fo...
HitIQ Issues 97.5 Million New Shares and Confirms Regulatory Compliance
Feb 25, 2026
HitIQ Limited has issued 97,474,962 fully paid ordinary shares, expanding its share capital base without a prospectus or other disclosure document under Part 6D.2 of the Corporations Act. The company has formally notified the market of this issuan...
HitIQ Seeks ASX Quotation for Nearly 97.5 Million New Shares
Feb 25, 2026
HitIQ Limited has applied for quotation on the ASX of 97,474,962 new ordinary fully paid shares, with an issue date of 25 February 2026. The move significantly increases the number of quoted securities on issue, indicating a notable capital-relate...
HitIQ Narrows Half‑Year Loss but Revenue Slips and Balance Sheet Remains Weak
Feb 25, 2026
HitIQ Limited reported a 3.2% decline in revenue to $997,178 for the half year ended 31 December 2025, while narrowing its after‑tax loss to $2,898,554, a 6.2% improvement from the prior corresponding period. The company did not declare any ...
HitIQ halts trading in HIQOA options amid Corporations Act issue
Feb 24, 2026
HitIQ Limited has requested and received an immediate voluntary suspension of its HIQOA listed options from quotation on the ASX, with the suspension applying only to this specific class of securities and not to the company’s other quoted se...
HITIQ Flags Compliance Lapses on Share Cleansing and HIQOA Option Quotation
Feb 24, 2026
HITIQ Limited has disclosed that it failed to lodge a required cleansing notice within the mandated five business days after issuing shares on 19 January 2026 due to an administrative oversight. The company’s review found that none of these ...
HitIQ Halts Trading as It Probes Potential Cleansing Notice Lapse
Feb 20, 2026
HitIQ Limited has requested and been granted a trading halt on its securities by the ASX while it investigates a potential inadvertent failure to lodge required cleansing notices for recently issued shares and listed options. The halt, expected to...
HITIQ Appoints New Joint Company Secretaries to Strengthen Governance
Feb 9, 2026
HITIQ Limited has appointed Mr Lachie Mallia and Ms Nova Taylor as joint company secretaries, replacing outgoing secretary Ms Michelle Sabatino. Mallia, a director at Bio101 Financial Advisory and an experienced CFO and company secretary in the he...
HITIQ Shareholders Back Funding and Director Fee Resolutions at 2026 General Meeting
Feb 6, 2026
HITIQ Limited, a concussion management technology company listed on the ASX, held its General Meeting on 6 February 2026, at which shareholders considered a suite of capital and remuneration-related resolutions. The meeting, where two previously f...
HitIQ Sets Agenda for 2026 General Meeting
Feb 6, 2026
HitIQ Limited has scheduled its 2026 General Meeting for 11:00am on Friday, 6 February 2026, with shareholders invited to attend under its ASX listing (ASX: HIQ). The meeting will cover formal business items including resolutions 1–10, notin...
HITIQ Boosts R&D Financing With Extra $500,000 Loan Drawdown
Feb 3, 2026
HITIQ Limited has drawn down an additional $500,000 from its existing RD Tax Incentive loan facility with No Bull Health Pty Ltd, lifting total borrowings under the arrangement to $1.23 million and providing early access to a further portion of it...
HitIQ Secures Exclusive Hockey Australia Deal in A$20–25m Player Safety Push
Feb 3, 2026
HitIQ Limited has signed an exclusive three-year national partnership with Hockey Australia, becoming the governing body’s Official Player Safety Partner and deploying its PROTEQT head-impact monitoring technology across the full hockey path...
HitIQ Director James Barrie Resigns but Retains Significant Shareholding
Jan 30, 2026
HitIQ Limited has announced that director James Barrie ceased to be a director of the company on 30 January 2026, with the change formally notified to the ASX under listing rule requirements. Barrie retains a direct holding of 70,000 fully paid or...
HITIQ Director and Company Secretary Resigns Over Potential Conflict of Interest
Jan 30, 2026
HITIQ Limited has announced the immediate resignation of Director and Company Secretary James Barrie, who stepped down after notifying the board of a potential future conflict of interest linked to another of his directorships. As a consequence, r...
HitIQ Accelerates Global Rollout of PROTEQT With North American Push, Retail Expansion and New Partnerships
Jan 30, 2026
HitIQ reported a pivotal December quarter as it accelerates from technology validation to commercial rollout of its PROTEQT concussion monitoring platform, securing an exclusive Canadian distribution deal that opens the North American collision-sp...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.